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Biomarkers of brain Ab amyloid deposition can be measured either by cerebrospinal ﬂuid Ab42 or Pittsburgh compound B
positron emission tomography imaging. Our objective was to evaluate the ability of Ab load and neurodegenerative atrophy on
magnetic resonance imaging to predict shorter time-to-progression from mild cognitive impairment to Alzheimer’s dementia and
to characterize the effect of these biomarkers on the risk of progression as they become increasingly abnormal. A total of
218 subjects with mild cognitive impairment were identiﬁed from the Alzheimer’s Disease Neuroimaging Initiative. The primary
outcome was time-to-progression to Alzheimer’s dementia. Hippocampal volumes were measured and adjusted for intracranial
volume. We used a new method of pooling cerebrospinal ﬂuid Ab42 and Pittsburgh compound B positron emission tomography
measures to produce equivalent measures of brain Ab load from either source and analysed the results using multiple imputation
methods. We performed our analyses in two phases. First, we grouped our subjects into those who were ‘amyloid positive’
(n=165, with the assumption that Alzheimer’s pathology is dominant in this group) and those who were ‘amyloid negative’
(n=53). In the second phase, we included all 218 subjects with mild cognitive impairment to evaluate the biomarkers in a
sample that we assumed to contain a full spectrum of expected pathologies. In a Kaplan–Meier analysis, amyloid positive
subjects with mild cognitive impairment were much more likely to progress to dementia within 2 years than amyloid negative
subjects with mild cognitive impairment (50 versus 19%). Among amyloid positive subjects with mild cognitive impairment
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all 218 subjects with mild cognitive impairment were combined (amyloid positive and negative), hippocampal atrophy and Ab
load predicted shorter time-to-progression with comparable power (hazard ratio for an inter-quartile difference of 2.6 for both);
however, the risk proﬁle was linear throughout the range of hippocampal atrophy values but reached a ceiling at higher values
of brain Ab load. Our results are consistent with a model of Alzheimer’s disease in which Ab deposition initiates the patho-
logical cascade but is not the direct cause of cognitive impairment as evidenced by the fact that Ab load severity is decoupled
from risk of progression at high levels. In contrast, hippocampal atrophy indicates how far along the neurodegenerative path one
is, and hence how close to progressing to dementia. Possible explanations for our ﬁnding that many subjects with mild
cognitive impairment have intermediate levels of Ab load include: (i) individual subjects may reach an Ab load plateau at
varying absolute levels; (ii) some subjects may be more biologically susceptible to Ab than others; and (iii) subjects with
mild cognitive impairment with intermediate levels of Ab may represent individuals with Alzheimer’s disease co-existent
with other pathologies.
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Introduction
The most widely accepted and validated biomarkers in Alzheimer’s
disease fall into two categories: imaging and CSF chemical
analytes (Shaw et al., 2007; Hampel et al., 2008). Different
biomarkers serve as in vivo indicators of speciﬁc pathologies.
Measures of brain atrophy on MRI are biomarkers of neurodegen-
erative pathology (Bobinski et al., 2000; Gosche et al., 2002; Jack
et al., 2002; Silbert et al., 2003; Jagust et al., 2008; Vemuri et al.,
2008b; Whitwell et al., 2008), while both PET amyloid imaging
(Klunk et al., 2004; Edison et al., 2007; Rowe et al., 2007;
Drzezga et al., 2008; Ikonomovic et al., 2008; Leinonen et al.,
2008; Frisoni et al., 2009; Tolboom et al., 2009) and decreased
CSF Ab42 (Clark et al., 2003; Strozyk et al., 2003; Schoonenboom
et al., 2008; Buchhave et al., 2009; Tapiola et al., 2009) are
indicators of brain Ab amyloidosis (referred to from here on as
Ab load).
One of the most meaningful clinical applications of Alzheimer’s
disease biomarkers is as an aid to predicting future clinical course.
Measures of brain atrophy on MRI are well-established predictors
of progression from mild cognitive impairment to Alzheimer’s
disease (Jack et al., 1999, 2005; Visser et al., 1999; Killiany
et al., 2000; Chetelat et al., 2005; Stoub et al., 2005;
Apostolova et al., 2006; Devanand et al., 2007; Vemuri et al.,
2008a; Davatzikos et al., 2009; Dickerson et al., 2009; Driscoll
et al., 2009; Fennema-Notestine et al., 2009; McEvoy et al.,
2009; Risacher et al., 2009). The presence of signiﬁcant brain
Ab load, measured either by CSF Ab42 or PET amyloid imaging,
is also highly correlated with progression from mild cognitive im-
pairment to Alzheimer’s disease (Hansson et al., 2006; Forsberg
et al., 2008; Brys et al., 2009; Mattsson et al., 2009; Okello et al.,
2009; Visser et al., 2009; Waragai et al., 2009; Wolk et al., 2009).
However, evidence indicates that Ab accumulation begins as
much as decades prior to the appearance of the ﬁrst cognitive
symptoms (Mintun et al., 2006; Peskind et al., 2006; Aizenstein
et al., 2008; Bouwman et al., 2009; Kok et al., 2009; Reiman
et al., 2009; Scheinin et al., 2009; Sperling et al.,
2009; Bourgeat et al., 2010;), while anatomical MRI becomes
abnormal later in the disease course (Fox et al., 1996, 2001;
Carlson et al., 2008). These ﬁndings suggest that the associations
between abnormalities in these two classes of biomarkers and the
‘time-dependent risk’ of progressing from mild cognitive impair-
ment to Alzheimer’s disease may differ, and this has not yet been
investigated to our knowledge.
We used a new method of transforming CSF Ab42 measures
into units of Pittsburgh compound B (PIB) PET (Weigand et al.,
2010) and pooled data from patients who had only one or the
other measure of Ab load using multiple imputation measurement
error models (Cole et al., 2006). Our objectives were to: (i) meas-
ure the ability of biomarkers of Ab load and neurodegeneration
(using MRI) to predict shorter time-to-progression from mild
cognitive impairment to Alzheimer’s disease; and (ii) determine
how the severity of these two categories of biomarker affects
the time-to-progression by estimating the log relative hazard
as a possible non-linear function of biomarker severity. To incorp-
orate the aetiological heterogeneity of subjects who meet clinical
criteria for mild cognitive impairment in our discussion, we
performed our analyses in two phases. In the ﬁrst, we grouped
our subjects into those who were ‘amyloid positive’, in whom we
assume Alzheimer’s disease is the dominant pathology, and those
who were ‘amyloid negative’. In the second phase, we included
all subjects with mild cognitive impairment in order to compare
MRI and Ab load biomarkers as predictors in a cohort that
included the full spectrum of expected pathologies associated
with the clinical syndrome of mild cognitive impairment.
Materials and methods
Subjects
A total of 218 subjects with a diagnosis of mild cognitive impairment
(Petersen et al., 2001) and one or more clinical follow-up assessments
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(ADNI) (Petersen et al., 2010). Subjects must have undergone either
lumbar puncture or PIB PET while carrying a diagnosis of mild cogni-
tive impairment. The primary outcome was time-to-progression from a
clinical diagnosis of mild cognitive impairment to Alzheimer’s disease.
The diagnosis of dementia was made using DSM-IV criteria (1994),
and the diagnosis of Alzheimer’s disease was made using established
clinical criteria (McKhann et al., 1984).
Magnetic resonance imaging methods
All subjects were scanned at 1.5 T with a 3D magnetization prepared
rapid acquisition gradient echo imaging sequence developed at the
Mayo Clinic Rochester for the Alzheimer’s Disease Neuroimaging
Initiative study (Jack et al., 2008). All images were corrected for
image distortion due to gradient non-linearity using ‘GradWarp’
(Jovicich et al., 2006), correction for B1 non-uniformity as necessary
(Jack et al., 2008) and for residual inhomogeneity using ‘N3’ (Sled
et al., 1998) with a software pipeline running at the Mayo Clinic
Rochester. Hippocampal volumes and total intracranial volumes were
measured at Mayo Clinic using FreeSurfer software (version 4.5.0)
(Fischl et al., 2002). Hippocampal volumes were adjusted for total
intracranial volumes by including total intracranial volumes as a
covariate in the Cox models (Jack et al., 1989).
Amyloid imaging methods
PIB PET studies were performed at 13 different sites. Production of PIB
PET and radio labelling with
11C was performed as outlined in Mathis
et al. (2003). The PIB PET images undergo several quality control and
standardization steps, which are described at http://www.ADNI-info
.org. The PIB PET images used in our study were the ‘maximally
pre-processed ﬁles’ available for download.
All PIB PET quantitative image analysis was performed at the Mayo
Clinic using the same fully automated image processing pipeline as
described in Senjem et al. (2008; Jack, 2008). The method includes
partial volume correction and region of interest sharpening of PIB PET
images using each subject’s spatially registered MRI. Statistics on
image voxel values were extracted from automatically labelled cortical
regions of interest using an in-house modiﬁcation of the automated
anatomic labelling atlas (Tzourio-Mazoyer et al., 2002). A global
cortical PIB PET retention summary was formed by combining the
prefrontal, orbitofrontal, parietal, temporal, anterior cingulate and
posterior cingulate/precuneus values for each subject, using a
weighted average of these regions of interest values where larger
regions of interest were given greater weight. PIB PET ratio values
were calculated by dividing the median value in each target cortical
region of interest by the median value in the cerebellar grey matter
region of interest of the atlas.
Cerebrospinal ﬂuid methods
CSF was collected at each site, transferred into polypropylene transfer
tubes followed by freezing on dry ice within 1h after collection and
shipped overnight to the Alzheimer’s Disease Neuroimaging Initiative
Biomarker Core laboratory at the University of Pennsylvania Medical
Centre on dry ice. A standardized protocol was implemented to quan-
tify biomarker concentrations in each of the CSF baseline aliquots
using a multiplex xMAP Luminex platform (Luminex Corp, Austin,
TX) with Innogenetics (INNO-BIA AlzBio3, Ghent, Belgium; for
research use only reagents) immunoassay kit-based reagents, validated
in Vanderstichele et al. (2008) and Shaw et al. (2009). Details can be
found at (http://www.adni-info.org/index.php).
Statistical methods
We used Cox proportional hazards models to estimate the effect of Ab
load and hippocampal volume on the relative hazard of progression
from mild cognitive impairment to Alzheimer’s disease. In Cox models,
increased relative hazard is directly related to shortened time-to-event.
Time 0 for each subject was deﬁned as the date of their earliest visit
with PIB PET imaging, or with CSF if the subject did not participate in
PIB PET imaging. The event time was deﬁned as the midpoint between
the last visit in which the subject was diagnosed with mild cognitive
impairment and the ﬁrst visit in which the subject was diagnosed as
demented. Subjects who were never observed to progress to dementia
were censored at their last visit. Two subjects who met the inclusion
criteria but progressed to a clinically diagnosed non-Alzheimer’s
dementia were censored at their event time because at this point
they were no longer at risk for Alzheimer’s dementia and in a time-
to-event analysis it would be inappropriate to remove these subjects
since they met the baseline inclusion criteria.
The primary predictors of interest were hippocampal volume with
total intercranial volumes included as a covariate and Ab load. To
allow for a non-linear relationship between the predictors and the
log hazard, we modelled the predictors using restricted cubic splines
with knots at the 10th, 50th and 90th percentiles (Harrell, 2001).
We report hazard ratios based on comparing the 25th, 50th and
75th percentiles to aid interpretability across biomarkers. The
25th percentile can be thought of as a typical ‘low’ value since it is
the middle value among those below the median (50th percentile).
Similarly, the 75th percentile can be thought of as a typical ‘high’
value. Since higher values of Ab are more abnormal while lower
values of hippocampal volume are more abnormal, a hazard ratio
comparing the 75th to the 25th percentile for Ab load is analogous
to one comparing the 25th to the 75th percentile for hippocampal
volume.
Throughout the manuscript, measures of brain Ab load are
expressed in the ‘cortical-to-cerebellar ratio units’, which are typically
used to measure PIB PET retention and range from 1.0 to 3.0. These
values are referred to as Ab load whether derived from CSF Ab42 or
actual PIB PET imaging. We used a multiple imputation measurement
error approach to transform CSF Ab42 into PIB PET units and pool
measures of Ab from either source (Cole et al., 2006). We describe the
necessary steps in detail elsewhere but brieﬂy summarize the method
here (Weigand et al., 2010). A calibration data set of 41 subjects who
participated in PIB PET imaging at the time of their lumbar puncture
was used to estimate the relationship between PIB PET retention (y),
CSF Ab42 (x) and whether the subject carries the APOE "4 allele (z).
The ﬁtted linear regression ‘conversion model’ was found to be:
log2(y)=5.3260.615 log2(x)+0.184(z)+e, where y is the estimated
PIB PET value that we call PIBcalc, x is the CSF-based value, z is 0 if
the subject carries no APOE "4 alleles and 1 if the subject is an "4
carrier, and e is a random error term that is normally distributed with
mean 0 and SD 0.180. While this formula can be used to obtain a
‘best guess’ estimate of a subject’s PIB PET retention, treating the
result as if it were obtained directly from PIB PET imaging is inappro-
priate because it ignores the error term in the conversion model and
the uncertainty associated with the conversion model coefﬁcients,
which are estimated rather than known exactly. To correctly carry
forward prediction uncertainty and model estimation uncertainty to
subsequent stages of the analysis, the multiple imputation measure-
ment error approach uses multiple imputation (Little and Rubin, 2002).
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set a subject’s Ab load value was the PIB PET value if available or a
simulated PIBcalc value otherwise. These simulated values incorporate
the error term from the conversion model plus an additional perturb-
ation to account for uncertainty in the conversion model parameters.
We then ﬁt a Cox proportional hazard model as described above to
each data set and pooled the results using the combining rules of
multiple imputation. We used multiple imputation likelihood ratio
tests to perform multiple degree of freedom tests of the linearity of
a biomarker predictor (Harel and Zhou, 2007). To compare progression
among those above versus below an Ab load level of 1.5, we
performed a Kaplan–Meier analysis on each multiple imputation data
set by dichotomizing the amyloid load variable at 1.5. Data manipu-
lation was performed using SAS version 9.1.3 (SAS Institute Inc., 2004)
and analysis was performed using R version 2.7.1. (R Development
Core Team, 2008). We used version 2.35-9 of the survival package
for R (Therneau, 2008) and version 2.0 of the mitools package for
R (Lumley, 2008).
Results
Analyses were performed in two phases. In the ﬁrst phase, we
used a generally accepted cut-off value reported in the PIB PET
literature of 1.5 to classify subjects as either ‘amyloid positive’
versus ‘amyloid negative’ (Rowe et al., 2007). Amyloid positive
subjects (n=165) were more frequently APOE "4 carriers,
performed slightly worse on the Clinical Dementia Rating Scale –
Sum of Boxes (CDR-SB) and had smaller hippocampal volumes at
baseline than amyloid negative subjects (n=53) (Table 1). Amyloid
positive subjects had a 3-fold increase in hazard of progressing
(hazard ratio 3.2, 95% CI 1.4–7.1, P=0.004) with Kaplan–Meier
analysis indicating 50% of amyloid positive subjects will progress
to dementia in 2 years versus 19% among amyloid negative.
Figure 1 illustrates MRI and PIB PET imaging ﬁndings in a typical
progressor and a typical non-progressor. With only eight progres-
sors among the amyloid negative group, relationships between
progression and biomarkers could not reliably be assessed.
Among the amyloid positive subjects, the hazard ratio (95% CI)
for progressing was 1.2 (0.9–1.8) (P=0.44) for an individual in the
75th versus 25th percentile of the Ab load distribution (whose
lower bound was by deﬁnition 1.5). The analogous hazard ratio
(95% CI) for the 25th versus 75th percentile of hippocampal
volume was 2.0 (1.5–2.8) (P50.001). The relationship between
log relative hazard of progressing and increasingly atrophic hippo-
campi was essentially linear (P=0.93, versus a non-linear
spline ﬁt).
Among all 218 subjects with mild cognitive impairment
combined, over a median progression-free follow-up time of
1.7 years, 89 subjects progressed from mild cognitive impairment
to dementia. In qualitative terms, age and education did not differ
between progressors and non-progressors, although women made
up a larger proportion of the progressors (Table 1). The progressor
group had a higher proportion of APOE "4 carriers, and slightly
worse scores on the Mini-Mental State Examination and Clinical
Dementia Rating Scale B than non-progressors at baseline.
Progressors had greater Ab load and more atrophic hippocampi
at baseline than non-progressors. Direct statistical comparisons of
progressor versus non-progressor are inappropriate because
follow-up times varied across individual subjects; hence our use
of time-to-event statistical methods with results reported as
hazard ratios. Among all subjects with mild cognitive impairment
the hazard ratio (95% CI) for progressing was 2.6 (1.5–4.5) for an
individual in the 75th versus 25th percentile of the Ab load distri-
bution. The analogous hazard ratio (95% CI) for the 25th versus
75th percentile of hippocampal volume was 2.6 (1.8–3.8). (The
percentiles being compared are reversed because greater Ab is
associated with greater risk, while smaller hippocampal volume is
associated with greater risk.) Both Ab load and MRI were highly
signiﬁcant predictors of progression overall (P0.001 for both)
(Table 2). The relationship between log relative hazard of pro-
gressing and increasingly atrophic hippocampi was essentially
linear (P=0.60 versus a non-linear spline ﬁt) (Fig. 2). In contrast
there was evidence of non-linearity (P=0.060) in this relationship
for Ab load—such that a ceiling was reached in the log relative
Table 1 Descriptive characteristics of all 218 subjects with mild cognitive impairment by progressor status, and by Ab load
status
Characteristic All Stable
a Progressor Amyloid
negative
(1.5)
Amyloid
positive
(`1.5)
Number of subjects n=218 n=129 n=89 n=53 n=165
Female gender, number (%) 72 (33) 38 (29) 34 (38) 13 (25) 59 (36)
Age, years, median (interquartile range) 75 (70, 80) 75 (70, 81) 75 (70, 80) 77 (70, 83) 75 (70, 80)
APOE positive, number (%) 117 (54) 58 (45) 59 (66) 7 (13) 110 (67)
Education, years, median (interquartile range) 16 (14, 18) 16 (14, 18) 16 (14, 18) 16 (14, 18) 16 (14, 18)
MMSE, median (interquartile range) 27 (25, 29) 28 (26, 29) 26 (25, 28) 28 (26, 29) 27 (25, 28)
CDR-SB, median (interquartile range) 1.5 (1.0, 2.0) 1.0 (1.0, 1.5) 2.0 (1.0, 2.5) 1.0 (1.0, 1.5) 1.5 (1.0, 2.0)
Hippocampal volume, cm
3, median (interquartile range) 6.3 (5.6, 7.1) 6.7 (6.0, 7.5) 5.9 (5.0, 6.5) 6.9 (5.6, 7.6) 6.2 (5.6, 6.8)
Ab, median (interquartile range) 2.0 (1.5, 2.3) 1.8 (1.4, 2.2) 2.2 (1.9, 2.3) 1.3 (1.3, 1.4) 2.2 (1.9, 2.4)
Number (%) who were amyloid ‘positive’ 165 (76) 84 (65) 81 (91) 0 (0) 165 (100)
Number (%) in whom Ab load was measured by PIB PET 53 (24) 35 (27) 18 (20) 19 (36) 34 (21)
CDR-SB=Clinical Dementia Rating-Sum of Boxes ; MMSE=Mini-Mental State Examination.
a Subjects remained stable through last follow-up at which point they were censored.
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severity on the hazard of progression is illustrated in the plotted
log relative hazard proﬁles in Fig. 2 and summarized quantitatively
in Table 2. The 25th versus 50th percentile hazard ratio (95% CI)
for hippocampal volume was 1.6 (1.3–1.8) while the 50th versus
75th percentile hazard ratio (95% CI) was similar at 1.7 (1.2–2.2).
In contrast, the 50th versus 25th percentile hazard ratio for Ab
(2.3, 95% CI 1.4–3.8) was twice as great as the 75th versus 50th
percentile hazard ratio (1.1, 95% CI 0.9–1.4).
Figure 2 illustrates relationships among biomarker levels, hazard
of progressing and also APOE genotype. Tick marks at the bottom
of each graph show the imaging data for individual progressor
versus stable subjects. APOE "4 carriers are represented with
gold tick marks and non-carriers are represented with blue tick
marks. Ab load and APOE "4 status are closely related, with
carriers more likely to have higher Ab load than non-carriers. In
contrast, a much weaker association is seen between APOE "4 and
hippocampal atrophy.
Discussion
Our major ﬁndings were the following: (i) amyloid positive
subjects with mild cognitive impairment were much more likely
to progress to a clinical diagnosis of Alzheimer’s disease than
amyloid negative subjects with mild cognitive impairment
(50 versus 19% by 2 years); (ii) among only amyloid positive
Figure 1 Illustrative images. Left: Mild cognitive impairment progressor, Top: positive PIB PET. Bottom: MRI illustrating atrophic hip-
pocampi and ventricular enlargement. Right: Mild cognitive impairment non-progressor. Top: negative PIB PET with non-speciﬁc white
matter retention but no cortical retention. Bottom: MRI illustrating normal hippocampi and no ventricular enlargement.
Table 2 Summary of hazard ratios from Cox proportional
hazard models within all 218 subjects with mild cognitive
impairment
Hazard ratio
(95% CI)
P
Hippocampal volume
a 50.001
25th versus 50th percentile (i.e. 5.6 versus 1.6) 1.6 (1.3, 1.8)
50th versus 75th percentile (i.e. 6.3 versus 7.1) 1.7 (1.2, 2.2)
25th versus 75th percentile (i.e. 5.6 versus 7.1) 2.6 (1.8, 3.8)
Ab load 50.001
50th versus 25th percentile (i.e. 2.0 versus 1.5) 2.3 (1.4, 3.8)
75th versus 50th percentile (i.e. 2.3 versus 2.0) 1.1 (0.9, 1.4)
75th versus 25th percentile (i.e. 2.3 versus 1.5) 2.6 (1.5, 4.5)
a Hippocampal volume model also includes total intercranial volumes as a
covariate.
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predicted shorter time-to-progression (P50.001) while amyloid
load did not (P=0.44); (iii) In contrast, when all 218 subjects
with mild cognitive impairment were combined (amyloid positive
and negative), hippocampal atrophy and brain Ab load predicted
time-to-progression with comparable power; and (iv) however,
among all subjects with mild cognitive impairment combined,
the effects of these two classes of biomarkers differ. The risk
proﬁle is linear throughout the range of hippocampal atrophy
values whereas the proﬁle reaches a ceiling at higher values of
brain Ab load.
Amyloid positive subjects with mild
cognitive impairment are more likely
to progress to a clinical diagnosis of
Alzheimer’s disease in short-term
follow-up than amyloid negative
subjects with mild cognitive impairment
Our results on Ab load predicting progression are consistent with
studies indicating that abnormally low CSF Ab42 is associated with
an elevated risk of progressing from mild cognitive impairment to
Alzheimer’s disease (Hansson et al., 2006; Kester et al., 2009;
Mattsson et al., 2009) or an approximate diagnostic equivalent
(Snider et al., 2009). Our results are also consistent with several
recent papers showing that individuals diagnosed with mild
cognitive impairment who have positive PIB PET scans are more
likely to progress to Alzheimer’s disease in short-term follow-up
than are subjects with mild cognitive impairment with negative PIB
PET scans (Forsberg et al., 2008; Okello et al., 2009; Wolk et al.,
2009). Although we did not examine cognitively normal elderly
subjects, recent reports indicate that both abnormal PIB PET
scans and low CSF Ab42 are associated with cognitive decline in
cognitively normal subjects (Skoog et al., 2003; Fagan et al.,
2007, 2009; Gustafson et al., 2007; Li et al., 2007; Stomrud
et al., 2007; Villemagne et al., 2008; Lambert et al., 2009;
Morris et al., 2009; Chetelat et al., 2010; Resnick et al., 2010).
Among only amyloid positive subjects
with mild cognitive impairment,
hippocampal atrophy predicts shorter
time-to-progression from mild cognitive
impairment to Alzheimer’s disease
while amyloid load does not
Evidence from multiple sources overwhelmingly points to Ab as
the initiating molecular pathway in Alzheimer’s disease pathogen-
esis. Many in the ﬁeld believe that mildly impaired subjects with
biomarker evidence of brain Ab amyloidosis can be presumed to
have early Alzheimer’s disease (Dubois et al., 2007; Morris et al.,
2009). In contrast, mildly impaired or demented individuals who
have negative Ab amyloid biomarker studies may be presumed to
have non-Alzheimer’s disease pathogenic substrates (Rabinovici
et al., 2007). Thus subjects with mild cognitive impairment who
are amyloid positive can be treated as qualitatively different from
those who are amyloid negative on conceptual grounds. Our
intent in the amyloid positive subset analysis was to compare
MRI and Ab load in those subjects with mild cognitive impairment
who probably have Alzheimer’s disease as the dominant
pathology. An obvious criticism of this analysis is that we have
restricted the range of Ab load values, thus handicapping Ab
measures relative to MRI. Hippocampal atrophy is not speciﬁc
for Alzheimer’s disease as it occurs in other degenerative
conditions (Jack et al., 2002), however, we can assume that
in a cognitively impaired subject with ‘pure Alzheimer’s disease
pathology’ the hippocampal atrophy observed is largely due to
the Alzheimer’s disease pathological process. By including the
full range of hippocampal values in this subset analysis, we have
Figure 2 Risk proﬁle as a function of increasing biomarker severity among all 218 subjects with mild cognitive impairment. Log hazard of
progressing to dementia as a function of (A) increasing hippocampal volume (adjusting for total intercranial volumes) and (B) increasing
brain Ab amyloid load within all 218 subjects with mild cognitive impairment. Hash marks at the bottom of the plot indicate the
hippocampal volume and Ab load measures of individual subjects with mild cognitive impairment, with APOE genotype ("4 carrier gold,
non-carrier blue) and progressor versus non-progressor status indicated.
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to the Alzheimer’s disease pathological process.
A recently described model of the Alzheimer’s disease
pathological cascade posits that the features of this cascade that
are detectable by well-established disease biomarkers begin
with detection of Ab deposition (Jack et al., 2009, 2010). This
model (referred to from here forward as a ‘biomarker cascade
model’) rests on the concept that biomarker abnormalities and
clinical expression of disease change over time in a sequential
manner. The disease process is initiated with Ab deposition and
substantial Ab deposition occurs while subjects are still cognitively
normal. However, Ab amyloidosis, while necessary, is not
sufﬁcient to cause Alzheimer’s dementia. Ab amyloidosis triggers
a downstream neurodegenerative process that in turn is the
proximate cause of cognitive impairment that progresses to
dementia (DeKosky and Scheff, 1990; Terry et al., 1991;
Bennett et al., 2005b; Jack et al., 2009; Mormino et al., 2009;
Savva et al., 2009).
This ‘biomarker cascade model’ (Jack et al., 2010) implies that
the development of dementia due to Alzheimer’s disease (as a
dichotomous yes/no event over the life time of any subject)
should be predicted by the aetiologically speciﬁc Ab biomarkers,
but time-to-dementia should be predicted by neurodegenerative
severity (atrophy on MRI). Our data are consistent with this model
in that amyloid positive subjects were far more likely to progress
within 2 years than amyloid negative subjects (50 versus 19%).
While Ab deposition initiates the pathological cascade, it is not the
direct cause of cognitive impairment. Accordingly, in our data Ab
load severity is decoupled from time-to-progression at high levels.
In contrast, hippocampal atrophy indicates how far along
the neurodegenerative path one is, and hence how close to
progressing to dementia (DeKosky and Scheff, 1990; Terry
et al., 1991; Jack et al., 2009; Mormino et al., 2009; Savva
et al., 2009), which again matches our data. Moreover, the log
relative hazard decreased linearly with increasing hippocampal
atrophy, indicating a direct relationship between severity of
atrophy and time-to-dementia. Figure 3A is a simpliﬁcation of
the ‘biomarker cascade model’ from Jack et al. (2010) with only
the Ab load and MRI neurodegenerative biomarkers displayed.
The ‘biomarker cascade model’ describes the cognitive and
biomarker trajectory of an individual who develops Alzheimer’s
disease dementia over his/her adult lifetime. In contrast, all
subjects in this paper began the study having already demon-
strated a cognitive impairment, which indicates that the process
of neurodegeneration had already begun. Over the time a subject
traverses the horizontal ‘clinical distance’ (indicated by the hori-
zontal red and blue arrows in Fig. 3A) from the time-of-diagnosis
of mild cognitive impairment to a time-of-diagnosis of dementia
(indicated by vertical lines in Fig. 3A), the vertical ‘distance
travelled’ along the Ab load biomarkers curve is small. In contrast,
over this same ‘clinical distance travelled’ on the horizontal axis,
the vertical distance travelled along the MRI biomarker is substan-
tial. Thus the position of a subject with mild cognitive impairment
along the MRI curve is a strong determinant of his/her time to
dementia. One important caveat is that follow-up times in our
sample, as in most published studies on mild cognitive impairment,
were relatively short, which limits our conclusions as to the
relationships between brain Ab load, brain atrophy and the risk
of progressing over a short interval of time (several years).
Conclusions related to longer term risk associated with these
two classes of Alzheimer’s disease biomarkers will require lengthier
follow-up.
Among all subjects with mild cognitive
impairment, combined hippocampal
atrophy and brain Ab load predict
progression with comparable power
An interesting feature of our data is that the results differ when
subjects with mild cognitive impairment are split into amyloid posi-
tive or negative, versus when all subjects with mild cognitive
impairment are examined together. When all subjects with mild
cognitive impairment are analysed together, hippocampal atrophy
and brain Ab load predict progression to dementia with compar-
able discriminative power. However, the risk proﬁle associated
with increasing severity of these two classes of biomarker differs
notably. The log relative hazard is linear throughout the range of
hippocampal atrophy values, which means that a unit decrease in
hippocampal volume has the same increase in relative hazard
(i.e. shortened time-to-progression) across the spectrum of hippo-
campal values. In contrast, for brain Ab load, the log relative
hazard is approximately linear from 1.0 through 2.0, at which
point it plateaus. This suggests that up to a value of 2.0 increas-
ing Ab confers commensurate shortened time-to-progression but
values beyond this threshold confer little or no additional apparent
relative hazard.
While there are several possible explanations for this ﬁnding,
one is the possible effect of coexistent pathologies. Mild cognitive
impairment is an aetiologically heterogeneous clinical diagnosis.
A proportion of subjects in most longitudinal cohorts of subjects
with mild cognitive impairment do not progress over long-term
clinical follow-up and are felt most likely to have non-progressive
conditions (DeCarli, 2003). Among subjects with mild cognitive
impairment who progressed from a clinical diagnosis of mild
cognitive impairment to dementia and then came to autopsy,
Jicha et al. (2006) found that 71% had typical Alzheimer’s
pathology. However, 29% had a ﬁnal primary neuropathological
diagnosis other than Alzheimer’s disease, including Lewy body
disease, hippocampal sclerosis, non-speciﬁc tauopathy, fronto-
temporal lobar dementia and cerebrovascular disease. In addition,
82% had two or more pathological processes that were felt
to contribute to dementia, including 35% with cerebrovascular
disease and 26% with Lewy body disease. Similar autopsy
ﬁndings in mild cognitive impairment have been reported by
others (Bennett et al., 2005a; Markesbery et al., 2006;
Schneider et al., 2009). The data in our mild cognitive impairment
combined group (n=218) can therefore be interpreted from
the perspective of certain aetiological heterogeneity. We can
safely assume that our total mild cognitive impairment
group contained: (i) subjects with Alzheimer’s pathology only;
(ii) subjects with no Alzheimer’s pathology (one of our subjects
did progress to semantic dementia and another to multi
system atrophy, both diagnosed clinically); (iii) subjects with mild
3342 | Brain 2010: 133; 3336–3348 C. R. Jack et al.cognitive impairment with mixed pathology, particularly
Alzheimer’s plus cerebrovascular disease or Lewy body disease.
While the autopsy numbers at this point are small, to date
10 of our subjects have come to autopsy bearing the clinical diag-
nosis of either mild cognitive impairment (n=2) or Alzheimer’s
dementia (n=8) at the time of death. Of these, four (40%) had
autopsy ﬁndings of Alzheimer’s pathology without any other
signiﬁcant co-morbidity and six (60%) had autopsy ﬁndings of
mixed Alzheimer’s pathology (Cairns et al., 2010). While subjects
with mixed pathology are not addressed by the ‘biomarker
Figure 3 Hypothetical effects of pure Alzheimer’s pathology versus mixed pathology on time-to-progression from mild cognitive
impairment to dementia. Clinical disease stage is indicated on the horizontal axis with vertical lines indicating the time at which diagnoses
of mild cognitive impairment and dementia are reached. The severity of Ab load (red curve) and brain atrophy (blue curve) on the vertical
axis range from normal to maximally abnormal. (A) [modiﬁed from Jack et al. (2010)], illustrates the hypothetical biomarker curves of
Subject A, who progresses from normal to mild cognitive impairment to dementia and who has pure Alzheimer’s pathology. Over the time
a subject traverses the horizontal ‘clinical distance’ from time-of diagnosis of mild cognitive impairment to time-of diagnosis of dementia
(indicated by the horizontal red and blue arrows), the vertical ‘distance travelled’ along the Ab load biomarkers curve is small as indicated
by the red vertical arrow in (A). In contrast, over this same ‘clinical distance travelled’ on the horizontal axis, the vertical distance travelled
along the MRI biomarker is substantial as indicated by the blue vertical arrow in (A). (B) illustrates the hypothetical curve of Subject B, who
has mixed pathology. The effect of the coexistent second pathology is to shift the blue atrophy curve, time-of diagnosis of mild cognitive
impairment, and time-of diagnosis of dementia closer to the Ab curve. Consequently Subject B reaches a diagnosis of dementia with a
lower level of Ab in situ than Subject A. AD=Alzheimer’s disease; MCI=mild cognitive impairment.
MRI versus amyloid MCI prediction Brain 2010: 133; 3336–3348 | 3343cascade model’ (Jack et al., 2010), in the next paragraph we
expand this model to incorporate the hypothetical effect of
coexistent pathologies.
To interpret our results more easily in light of the ‘biomarker
cascade model’ (Jack et al., 2010), we divided our amyloid posi-
tive group (n=165) into 113 subjects with high Ab load (42.0)
and 52 subjects with intermediate Ab load (1.5–2.0). Subjects
with mild cognitive impairment and intermediate Ab load levels
do not completely ﬁt the ‘biomarker cascade model’, because
the model predicts that by the time a subject is sufﬁciently
impaired to reach a clinical diagnosis of mild cognitive impairment,
he/she already has accumulated a substantial Ab load. There are
several possible explanations for this: some subjects may reach
a plateau at lower absolute levels of Ab load, some subjects
may be more biologically susceptible to Ab or levels of soluble
Ab oligomers may be more critical than ﬁbrillar Ab levels. One
interesting possibility, however, is that subjects with mild cognitive
impairment and intermediate levels of Ab probably represent
individuals with mixed Alzheimer’s-other pathology. The propor-
tion of APOE "4 carriers among the subjects with high Ab load
and mild cognitive impairment was 84%, but only 29% among
the subjects with intermediate Ab load and mild cognitive
impairment. This supports the idea that those with intermediate
Ab load values in our sample were more likely to have co-morbid
non-Alzheimer’s pathologies contributing to cognitive impairment
than the subjects with high Ab load. Cerebrovascular disease is
the second most common pathological substrate associated with
dementia in most autopsy series (Schneider et al., 2004, 2007a;
Sonnen et al., 2007). Recent work suggests that micro infarction
in particular is a key cerebrovascular disease pathology that
contributes to cognitive impairment (Petrovitch et al., 2005;
White et al., 2005; Sonnen et al., 2007; Schneider et al., 2009).
The implication is that cerebrovascular disease is a separate
pathway to degenerative brain atrophy (Jagust et al., 2008) that
has an additive effect on cognition along with the neurode-
generation initiated by amyloidosis (Schneider et al., 2007b,
2009; Jagust et al., 2008).With both amyloidogenic and cerebro-
vascular disease pathologies in operation, an individual can receive
a diagnosis of mild cognitive impairment with a lower level of
amyloid pathology than an individual with only amyloid-initiated
degenerative pathology. We illustrate this effect hypothetically in
Fig. 3. Whereas Fig. 3A shows a subject with pure Alzheimer’s
pathology, Fig. 3B shows a hypothetical subject with mixed
Alzheimer’s-cerebrovascular disease pathology. Hypothetical
curves for Ab load and hippocampal atrophy are indicated as
non-linear functions of time and are indexed to the points at
which diagnoses of mild cognitive impairment and dementia
are made (indicated by vertical lines). We model the effect of
combined pathology in Fig. 3B as a decrease in the temporal
separation between the Ab amyloid curve and the complex
comprised of the brain atrophy curve and the vertical markers
indicating time-of-mild cognitive impairment and dementia
diagnoses. The effect is that Subject B becomes demented with
lower levels of Ab load than Subject A, however, the linear
relationship between brain atrophy and time to dementia is
the same for both subjects. Note that in Fig. 3B we do not
intend to imply that subjects with mixed pathology necessarily
reach a diagnosis of dementia at a younger age, but rather
do so with a lower Ab level than subjects with pure Alzheimer’s
pathology. We acknowledge that this explanation is speculative
because we cannot know the status of co-existent pathologies in
individual subjects ante mortem. However, there is no reason to
suspect that the subjects with mild cognitive impairment enrolled
in the Alzheimer’s Disease Neuroimaging Initiative are notably
different from subjects with mild cognitive impairment in earlier
autopsy studies where the prevalence of coexistent pathologies
has been consistently well documented.
‘Brain Ab load’ measurement:
converting cerebrospinal ﬂuid Ab42
measures to Pittsburgh compound B
positron emission tomography units and
combining measures across subjects
Ab load was ascertained by CSF in 165 subjects and by PIB PET
imaging in 53 subjects. We recognize that using only global Ab
load values ignores potentially useful regional information in PIB
PET images. We also emphasize the limitations inherent in pooling
CSF and PIB PET data. However, pooling subjects with either CSF
or PIB PET increased our sample size and improved statistical
power by increasing the number of progression events. In our
case, the increased sample size was necessary to adequately
power the evaluation of non-linearity in the MRI and Ab load
risk proﬁles. Justiﬁcation for pooling CSF and imaging-based meas-
urements is the consistently observed tight inverse correlation be-
tween PIB PET and CSF Ab42 measures in every study where the
two measures have been compared (Fagan et al., 2006; Forsberg
et al., 2008; Grimmer et al., 2009; Jagust et al., 2009; Degerman
Gunnarsson et al., 2010). We used the multiple imputation meas-
urement error (Cole et al., 2006) method of transforming CSF
Ab42 into PIB PET units to produce statistically equivalent meas-
ures of Ab load from either biomarker source (Weigand et al.,
2010). The multiple imputation measurement error method
assumes that two measures of the same biological phenomenon
exist. One is the ‘gold standard’; the second is a surrogate meas-
urement with associated measurement error. We considered PIB
PET imaging to be the more direct measure of Ab load in the brain
and CSF-based Ab42 to be a surrogate measured with additional
error. Our approach can therefore be thought of as calibrating or
adjusting the ﬁndings from CSF to the more accurate imaging
based measure while taking into account uncertainty in the
calibration process.
One concern we had was that the non-linear log relative hazard
of Ab load illustrated in Fig. 2 could be an artefact of the model
transforming CSF Ab42 into PIB PET units. To address this, we also
performed the time-to-event analysis on the rank-transformed Ab
load. Our ﬁndings of non-linearity of Ab load and linearity of
hippocampal volume did not change using this rank-based
analysis. Because the rank-transformed values would be the
same under any reasonable progression model, we concluded
that the non-linearity in the time-to-event data reﬂects a real
biological property of Ab load and not a feature of the relationship
3344 | Brain 2010: 133; 3336–3348 C. R. Jack et al.between PIB PET and CSF Ab42. In addition, Fig. 2 illustrates that
APOE "4 carriers are more likely to have higher Ab load than
non-carriers. That is, the established property of APOE "4 as pri-
marily a risk factor for brain Ab deposition (Schmechel et al.,
1993; Morris et al., 2010; Vemuri et al., 2010) is maintained
when the Ab load is measured from pooling CSF and PIB PET
data.
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